Records containing: Recurrent Bladder Carcinoma
This is the wording recorded or indexed by the source. An agency index term is not necessarily an authorised indication. Co-listed drug names are not linked to this term as a treatment relationship.
Follow recorded terms in Drug Alerts for Android. Free includes unlimited local condition follows and an on-open recent-record watchlist. Plus adds no ads and personal organization tools.
All
FDA submission records
EMA medicine records
ClinicalTrials.gov record updates
ClinicalTrials.gov records with results posted
-
CLINICAL_TRIALS study record update · 2026-04-13Molecular Analysis for Therapy Choice (MATCH)
-
CLINICAL_TRIALS study record update · 2026-01-27A Scalable Cruciferous Vegetable Intervention to Reduce Bladder Cancer Recurrence and Progression
-
CLINICAL_TRIALS study record update · 2026-01-15Molecular Correlates of Sensitivity and Resistance to Therapy in Genitourinary Malignancy
-
CLINICAL_TRIALS study record update · 2025-02-11An Open Label, Multicenter, Single Arm Phase II Study to Evaluate the Activity and Tolerability of the Novel mTOR Inhibitor, MLN0128 (TAK-228), in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelial Tract Whose Tumors Harbor a TSC1 and/or a TSC2 Mutation
-
CLINICAL_TRIALS study record update · 2025-02-07A Phase 1 and Pharmacokinetic Single Agent Study of Romidepsin in Patients With, Lymphomas, Chronic Lymphocytic Leukemia, and Select Solid Tumors and Varying Degrees of Liver Dysfunction
- Organize your saved records without ads with Plus.
-
CLINICAL_TRIALS study record update · 2023-12-06A Phase I Study to Evaluate the Safety of Trigriluzole (FC-4157/BHV-4157) in Combination With PD-1 Blocking Antibodies
-
CLINICAL_TRIALS study record update · 2023-06-26A First-in-Human Phase I Study of Intravesical sEphB4-HSA in Patients With "BCG-Unresponsive" Bladder Carcinoma In Situ (CIS), Completely Resected High Grade Ta/T1, to Establish the Maximum Tolerated Dose (MTD) or Recommended Phase II Dose (RP2D)
-
CLINICAL_TRIALS study record update · 2022-10-20A Phase 1 Dose-Escalation Study of Intravesical MK-3475 and Bacillus Calmette-Guerin (BCG) in Subjects With High Risk and BCG-Refractory Non-Muscle-Invasive Bladder Cancer
-
CLINICAL_TRIALS study record update · 2022-10-18Feasibility Trial of MK3475 + Docetaxel or Gemcitabine in Platinum Pre-treated Urothelial Cancer
-
CLINICAL_TRIALS study record update · 2021-11-24A Pilot Study of Neoadjuvant sEphB4-HSA in Patients With Genitourinary Cancers
-
CLINICAL_TRIALS study record update · 2020-07-07Phase II Clinical Chemoprevention Trial of Weekly Erlotinib Before Bladder Cancer Surgery
-
CLINICAL_TRIALS study record update · 2019-06-06A Pilot Study of a Rapid Access Platform for Investigational Drugs (RAPID) in Advanced Cancers
-
CLINICAL_TRIALS study record update · 2017-10-20A Phase 1-2 Study of Rapamycin and Cisplatin/Gemcitabine for Treatment of Patients With Bladder Cancer
-
CLINICAL_TRIALS study record update · 2016-10-04A Phase I Clinical Trial of mTOR Inhibition With Rapamycin for Enhancing Intranodal Dendritic Cell Vaccine Induced Anti-tumor Immunity in Patients With NY-ESO-1 Expressing Solid Tumors
-
CLINICAL_TRIALS study record update · 2016-03-24Phase II Study of Isoflavone G-2535 (Genistein) in Patients With Bladder Cancer
-
CLINICAL_TRIALS study record update · 2014-12-23Phase I Study of Intravesical Recombinant Fowlpox - GM-CSF (rF-GM-CSF) and/or Recombinant Fowlpox-TRICOM (rF-TRICOM) in Patients With Bladder Carcinoma Scheduled for Cystectomy